跳转至内容
Merck

C0410000

Canrenone

European Pharmacopoeia (EP) Reference Standard

别名:

(17α)-17-Hydroxy-3-oxopregna-4,6-diene-21-carboxylic acid γ-lactone, NSC 261713

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H28O3
CAS号:
分子量:
340.46
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

canrenone

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

C[C@@]12C(C=C[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@]45OC(CC5)=O)=CC(CC1)=O

InChI

1S/C22H28O3/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21)12-8-19(24)25-22/h3-4,13,16-18H,5-12H2,1-2H3/t16-,17+,18+,20+,21+,22-/m1/s1

InChI key

UJVLDDZCTMKXJK-WNHSNXHDSA-N

基因信息

human ... NR3C2(4306)

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Canrenone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazardEnvironment

警示用语:

Warning

危险声明

预防措施声明

危险分类

Aquatic Chronic 2 - Carc. 2 Oral

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Saurav Chatterjee et al.
The American journal of medicine, 125(8), 817-825 (2012-07-31)
Eplerenone is publicized to be extremely effective in reducing mortality from heart failure, with a reasonable side-effect profile. However, it is much more expensive compared with older aldosterone antagonists. We reviewed available evidence to assess whether increased expense was justified
Victor Voicu et al.
Bioanalysis, 3(12), 1343-1356 (2011-06-18)
The inherent reproducibility of a bioanalytical approach is usually sustained through incurred sample reanalysis (ISR). Questions relating to the number of ISRs, the right moment for performing reanalysis, the way of performing an appropriate statistical refinement of experimental data and
G de Simone et al.
Nutrition, metabolism, and cardiovascular diseases : NMCD, 21(10), 783-791 (2011-09-24)
We analyzed the effect of the mineralocorticoid receptor antagonist canrenone on LV mechanics in patients with or without metabolic syndrome (MetS) and compensated (Class II NYHA) heart failure (HF) with reduced ejection fraction (EF≤45%) on optimal therapy (including ACE-i or
Alessandro Boccanelli et al.
Journal of cardiovascular medicine (Hagerstown, Md.), 8(9), 683-691 (2007-08-19)
Excess aldosterone activity contributes to the pathogenesis and progression of heart failure (HF). Aldosterone antagonists improve clinical outcome in patients with severe HF or left ventricular (LV) dysfunction after myocardial infarction, but knowledge of their impact in mild chronic HF
Federico Bilotta et al.
Neurocritical care, 16(2), 280-285 (2011-11-22)
Mannitol therapy to treat cerebral edema induces osmotic diuresis and electrolyte loss. In neurocritical care patients, potassium is the electrolyte that most often needs replacement. Objective of this study was to evaluate the effects of adding potassium sparing diuretic (canrenone)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持